HTA Quarterly | Spring 2019

By Xcenda |

In this issue, we explore the proposed rule from the Centers for Medicare & Medicaid Services on managed care value-based formulary decisions and consider how patient input can help influence drug development.

Heard on the Street

“For the first time in Canada, drug evaluation and price negotiation could be carried out by a single entity—resulting in lower prescription drug prices for Canadians and their families. By acting as a single evaluator and negotiator on behalf of Canada’s drug plans, the proposed agency could reduce drug spending by billions of dollars per year, compared to baseline projections, within 10 years of implementation.”

– Canadian Finance Minister Bill Morneau, presenting the proposed budget on March 19. The budget calls for creation of a new drug agency that would be responsible for both assessing the effectiveness of approved medicines and negotiating prices with a goal of reducing costs. The agency would also establish a national formulary and create consistent drug coverage across the country. 

HTA by the Numbers

£1 Billion
NHS England has entered into a £1 billion agreement with Gilead Sciences, Merck & Co., and AbbVie to purchase hepatitis C drugs at competitive prices in an effort to eradicate hepatitis C over the next 3 years.